

560264 ·
BDB Bioscience · Cat: 560264
Reach 3+ verified distributors
Manufacturer product page
bdbiosciences.com/en-us/products/reagents/flow-cytometry-rea...
Description
Flow cytometric analysis of IL-21 receptor CD360 in human peripheral lymphocytes. Whole blood was stained simultaneously with FITC Mouse Anti-Human CD19 Cat. No. 555412 and PE Mouse Anti-Human IL-21 Receptor CD360 Cat. No. 560264; right panel or PE Mouse IgG1, kappa Isotype Control Cat. No. 554680; left panel . Erythrocytes were lysed with BD Pharm Lyse Lysing Buffer Cat. No. 555899 . Two-color dot plots depicting IL-21 receptor CD360 or Ig isotype control versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur System. Flow cytometric analysis of IL-21 receptor CD360 in human peripheral lymphocytes. Whole blood was stained simultaneously with FITC Mouse Anti-Human CD19 Cat. No. 555412 and PE Mouse Anti-Human IL-21 Receptor CD360 Cat. No. 560264; right panel or PE Mouse IgG1, kappa Isotype Control Cat. No. 554680; left panel . Erythrocytes were lysed with BD Pharm Lyse Lysing Buffer Cat. No. 555899 . Two-color dot plots depicting IL-21 receptor CD360 or Ig isotype control versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur System. Flow cytometric analysis of IL-21 receptor CD360 in human peripheral lymphocytes. Whole blood was stained simultaneously with FITC Mouse Anti-Human CD19 Cat. No. 555412 and PE Mouse Anti-Human IL-21 Receptor CD360 Cat. No. 560264; right panel or PE Mouse IgG1, kappa Isotype Control Cat. No. 554680; left panel . Erythrocytes were lysed with BD Pharm Lyse Lysing Buffer Cat. No. 555899 . Two-color dot plots depicting IL-21 receptor CD360 or Ig isotype control versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur System. Show More Flow cytometric analysis of IL-21 receptor CD360 in human peripheral lymphocytes. Whole blood was stained simultaneously with FITC Mouse Anti-Human CD19 Cat. No. 555412 and PE Mouse Anti-Human IL-21 Receptor CD360 Cat. No. 560264; right panel or PE Mouse IgG1, kappa Isotype Control Cat. No. 554680; left panel . Erythrocytes were lysed with BD Pharm Lyse Lysing Buffer Cat. No. 555899 . Two-color dot plots depicting IL-21 receptor CD360 or Ig isotype control versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur System. Show More Flow cytometric analysis of IL-21 receptor CD360 in human peripheral lymphocytes. Whole blood was stained simultaneously with FITC Mouse Anti-Human CD19 Cat. No. 555412 and PE Mouse Anti-Human IL-21 Receptor CD360 Cat. No. 560264; right panel or PE Mouse IgG1, kappa Isotype Control Cat. No. 554680; left panel . Erythrocytes were lysed with BD Pharm Lyse Lysing Buffer Cat. No. 555899 . Two-color dot plots depicting IL-21 receptor CD360 or Ig isotype control versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur System. Flow cytometric analysis of IL-21 receptor CD360 in human peripheral lymphocytes. Whole blood was stained simultaneously with FITC Mouse Anti-Human CD19 Cat. No. 555412 and PE Mouse Anti-Human IL-21 Receptor CD360 Cat. No. 560264; right panel or PE Mouse IgG1, kappa Isotype Control Cat. No. 554680; left panel . Erythrocytes were lysed with BD Pharm Lyse Lysing Buffer Cat. No. 555899 . Two-color dot plots depicting IL-21 receptor CD360 or Ig isotype control versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur System.







